Treatment of Asymptomatic Bacteriuria in Pregnancy

Sponsor
Saint Joseph Mercy Health System (Other)
Overall Status
Terminated
CT.gov ID
NCT02911662
Collaborator
(none)
13
1
2
16
0.8

Study Details

Study Description

Brief Summary

This is a prospective randomized controlled day comparing the efficacy of three-day antimicrobial treatment of asymptomatic bacteriuria (ASB) in pregnancy to the standard seven-day treatment. Half the patients will receive 3-day treatment and the other half will receive 7 days of antibiotics.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

The current standard of practice is to treat pregnant patients with ASB with a 7-day course of oral antimicrobial agents. If bacteriuria persists women are retreated with the same of different agent for a second course of 7 to 14 days and they may be subsequently placed on prophylaxis.

In nonpregnant women, an uncomplicated lower urinary tract infection may be treated with a short course regimen from 1 to 3 days. This approach has similar rates of persistent bacteriuria or symptoms following treatment when compared to women treated with a more conventional approach. If the infection recurs or persists, the patient may then be treated with the more traditional 7 to 14 day course. The advantages of single-dose regimens are cost and patient compliance, but a major disadvantage is the failure to eradicate uropathogens from the vaginal reservoir, which results in more frequent early recurrences.

The three-day regimen is advocated to maintain the advantages of lower costs and patient compliance but improving cure rates. Multiple studies have shown the advantage of even a short course of antibiotics as opposed to no treatment.

Study Design

Study Type:
Interventional
Actual Enrollment :
13 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Study Start Date :
Sep 1, 2016
Actual Primary Completion Date :
Jan 1, 2018
Actual Study Completion Date :
Jan 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: 3-day treatment

Three-day treatment with Cephalexin or Nitrofurantoin for diagnosis of asymptomatic bacteriuria in pregnancy.

Drug: Cephalexin
Cephalexin will be prescribed for women with a positive urine culture but no symptoms of urinary tract infection.
Other Names:
  • Keflex
  • Drug: Nitrofurantoin
    Macrobid will be prescribed for women allergic to penicillin with a positive urine culture but no symptoms of urinary tract infection.
    Other Names:
  • Macrobid
  • Active Comparator: 7-day treatment

    Seven-day treatment with Cephalexin or Nitrofurantoin for diagnosis of asymptomatic bacteriuria in pregnancy.

    Drug: Cephalexin
    Cephalexin will be prescribed for women with a positive urine culture but no symptoms of urinary tract infection.
    Other Names:
  • Keflex
  • Drug: Nitrofurantoin
    Macrobid will be prescribed for women allergic to penicillin with a positive urine culture but no symptoms of urinary tract infection.
    Other Names:
  • Macrobid
  • Outcome Measures

    Primary Outcome Measures

    1. Evidence that 3-day treatment is as effective as 7-day treatment of asymptomatic bacteriuria in pregnancy. [Within 21 days of treatment]

      Comparison of percentage of women in each group with successful treatment or asymptomatic bacteriuria with negative urine culture 2 weeks after randomized treatment.

    Secondary Outcome Measures

    1. Comparison of development of cystitis during pregnancy. [Until 6 weeks postpartum]

      Comparison of percentage of women in each group who develop cystitis during pregnancy and the postpartum period.

    2. The occurence of preterm delivery [Assessed at the time of delivery]

      Comparison of the percentage of women in each group who deliver at <37 weeks gestation.

    3. Comparison of development of pyelonephritis during pregnancy [Until 6 weeks postpartum]

      Comparison of percentage of women in each group who develop pyelonephritis during pregnancy and the postpartum period.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Pregnant women ≥ 18 years of age seeking prenatal care at the Academic Obstetrics and Gynecology Center at St. Joseph Mercy Hospital, Ann Arbor, Michigan

    • Randomization will occur if the patient every has a urine culture demonstrating ≥10,000 cfu/ml of a pathogenic urinary tract organism

    Exclusion Criteria:
    • Symptomatic bacteriuria (cystitis or pyelonephritis) at the time of urine collection

    • Previously treated bacteriuria in current pregnancy

    • Past medical history of known congenital or acquired urinary tract anomaly or abnormality (i.e. pelvic kidney, single kidney, renal transplant)

    • Any antibiotic use within the week prior to urine sampling

    • Urine culture revealing growth of the following organisms: Lactobacillus, coagulase-negative staphylococcus

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 St. Joseph Mercy Hospital Ypsilanti Michigan United States 48197

    Sponsors and Collaborators

    • Saint Joseph Mercy Health System

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Pooja Green, Director of Obstetrical Research, Saint Joseph Mercy Health System
    ClinicalTrials.gov Identifier:
    NCT02911662
    Other Study ID Numbers:
    • HSR-16-1661
    First Posted:
    Sep 22, 2016
    Last Update Posted:
    Apr 18, 2018
    Last Verified:
    Apr 1, 2018
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 18, 2018